REGN / Regeneron CEO on the prospects for its eye drug Eylea

Regeneron Pharmaceuticals Inc.'s stock REGN, +1.46% rose fractionally on Thursday after the drug maker said its profit dropped by 23%, while its adjus more_horizontal

Regeneron Pharmaceuticals on Thursday beat Wall Street estimates for third-quarter profit, driven by strong demand for its eczema treatment Dupixent. more_horizontal

Besides Wall Street's top -and-bottom-line estimates for Regeneron (REGN), review projections for some of its key metrics to gain a deeper understandi more_horizontal

Healthcare stocks, on balance, haven't been great investments in 2023. Regeneron Pharmaceuticals and Vertex Pharmaceuticals have been two glaring exce more_horizontal

Regeneron (REGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely bea more_horizontal

Regeneron recently earned a key regulatory approval. The company also expanded its pipeline with an acquisition. more_horizontal

TARRYTOWN, N.Y., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its third quart more_horizontal

Regeneron's sales growth rate has been struggling over the past year. Revenue from its top-selling drug, Eylea, fell 7% in the most recent quarter. more_horizontal